Skip to main content


Figure 1 | BMC Medicine

Figure 1

From: Managing HIV/hepatitis C co-infection in the era of direct acting antivirals

Figure 1

Optimal duration of dual HCV therapy in HCV/HIV co-infected patients not eligible for triple therapy. (adapted with permission from Legend: i) Where no access to DAA is available or high chances of cure even with dual therapy (favorable IL28B genotype, low HCV viral load and no advanced fibrosis). ii) In patients with baseline low viral load (<600,000 IU/mL) and minimal liver fibrosis. DAA, direct acting antivirals; HCV, hepatitis C virus.

Back to article page